| CF |
Report |
Q2 2026 net sales |
BEAT |
pred ~$2.52B vs. cons $2.47B |
MEDIUM |
| CF |
Report |
Q2 2026 adjusted EBITDA |
BEAT |
pred ~$1.62B vs. cons $1.58B |
MEDIUM |
| CF |
Report |
Q2 2026 diluted EPS |
BEAT |
pred ~$5.84 vs. cons $5.70 |
MEDIUM |
| CF |
Guide |
Gross ammonia production |
UNCHANGED |
guide ~9.5M tons vs. cons 9.5M tons (FY2026) |
HIGH |
| CF |
Guide |
Consolidated capital expenditures |
UNCHANGED |
guide ~$1.30B vs. cons $1.30B (FY2026) |
HIGH |
| CF |
Guide |
India urea import outlook |
LOWER |
guide ~9.5M metric tons vs. cons 11.0M metric tons (FY2026) |
MEDIUM |
| CF |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.2% |
— |
MEDIUM |
| CF |
Return |
5-day cumulative residual |
-4.8% (FOLLOW-THROUGH) |
A modest Q2 beat is likely to be outweighed by softer out-period nitrogen assumptions: lower India import needs, returning Chinese exports and prospective Hormuz normalization imply FY2027 EPS revisions below the current ~$11.03 consensus, extending the initial negative residual move. |
MEDIUM |